LEIDEN, NETHERLANDS--(Marketwire - December 12, 2011) - Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announces that the
States Patent and Trademark Office (USPTO) has granted the Company U.S.
8,071,532, covering a method of preventing, reducing or treating an
and/or reperfusion injury by administering recombinant C1 inhibitor
(Ruconest(®)/ Rhucin(®)). The broad claims in the patent provide
until 2028. This is Pharming's first patent granted on ischemia/reperfusion
injury in the U.S., and represents a significant milestone in the
development of the Company's C1 inhibitor franchise in additional
associated with reperfusion injury such as Delayed Graft Function (DGF) and
Acute Myocardial Infarction (AMI).
The patent relates to a novel method of using recombinant C1 inhibitor
INH), being produced either in cell cultures or in transgenic animals,
rhC1 INH is administered after the onset of ischemia or the start of
reperfusion. Recombinant C1 inhibitor showed - in contrast to
inhibitor - to be still therapeutically active in a time span of 6 hours
therefore particularly useful for unforeseen occurrences of ischemic
such as stroke and myocardial infarction, whereas other claims are directed
treatment during organ transplantations.
Sijmen de Vries, Pharming's CEO said: "We are very pleased with this new
which further enhances the IP portfolio surrounding our proprietary
platform. In addition, it provides Pharming with an even stronger IP
for the potential expansion of our C1 inhibitor franchise into additional
clinical indications associated with reperfusion injury, such as DGF and
which are significant, commercially attractive markets associated with high
unmet clinical needs."
Pharming's intellectual property portfolio includes a number of issued
both in the United States and in various other countries, related to the
Company's proprietary rabbit based platform, unique to Pharming. The
industrialization of this platform by Pharming has been validated by the EU
approval of the rhC1 INH, Ruconest(®,) and provides unique properties
the development of complex proteins that to date have not been produced in
economically viable way.
Furthermore the industrial application of Pharming's rabbit platform
certain know-how elements specific to Pharming which contribute to
lower capital risk and manufacturing expenditures as well as delivering a
flexible supply chain than with any other biologicals production platforms,
including larger transgenic animals. It is from this rabbit based platform
Pharming plans to create new development assets to further broaden its
This patent can be viewed by going to the U.S. Patent Office Web
site,http://patents.uspto.gov, selecting the search patents screen, and
in the patent number 8,071,532.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of
medical needs. RUCONEST® (RHUCIN® in non-European territories) is
human C1 inhibitor approved for the treatment of angioedema attacks in
with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and
distributed in the EU by Swedish Orphan Biovitrum. Rhucin® is
Santarus Inc (NASDAQ: SNTS) in North America where the drug is undergoing
III clinical development. The product is also being evaluated for follow-on
indications in the areas of transplantation and reperfusion injury. The
technologies of the Company include innovative platforms for the production
protein therapeutics, technology and processes for the purification and
formulation of these products. Additional information is available on the
This press release contains forward looking statements that involve known
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially
from the results, performance or achievements expressed or implied by these
forward looking statements.
Press release (PDF) :
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.